Results

Total Results: 2,208 records

Showing results for "drug".

461. Diabetes Mellitus (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/07_diabetes_potential_high_impact_june_2012.pdf
     January 01, 2012 - Food and Drug Administration (FDA) treatment investigational new drug program to patients in the United … Food and Drug Administration (FDA) guideline for CLS studies. … Food and Drug Administration (FDA); 2011 Dec 1 [accessed 2012 Apr 10]. [2 p]. … Food and Drug Administration (FDA); 2011 Dec 1 [accessed 2011 Dec 15]. [2 p]. … Food and Drug Administration (FDA); 2011 Feb 16 [accessed 2011 May 23]. [2 p].

462. Diagnosis and Comparative Effectiveness of Treatments for Urinary Incontinence in Adult Women | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/urinary-incontinence-treatment/research-protocol
     December 01, 2020 - efficacy and comparative effectiveness of the pharmacological agents that were approved by the Food and Drug … Drug therapy for stress urinary incontinence: 18 Seratonin-noradrenaline uptake inhibitors: Duloxetine … We will review the effects of different drug formulations (by doses and routes of administration) on … UI, harms after treatment, or secondary outcomes that are listed above; Eligible interventions of drug … Food and Drug Administration, 5630 Fishers Lane, Room 1061.

463. Pneumonia-Antibiotic-Treatment Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/pneumonia-antibiotic-treatment_executive.pdf
     November 01, 2014 - Intravenous antibiotics for which PK/PD measures could be used Drug Class Drug Subclass Druga Aminoglycosides … PK is the study of the time course of drug absorption, distribution, metabolism, and excretion. … Optimizing drug exposure to minimize selection of antibiotic resistance. … Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. … Clin Drug Invest. 1999(2):133-9. 30. Hanes SD, Wood GC, Herring V, et al.

464. Urinary-Incontinence-Treatment Surveillance (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/urinary-incontinence-treatment_surveillance.pdf
     October 29, 2012 - The Food and Drug Administration (FDA), Health Canada, and Medicines and Healthcare products Regulatory … would produce prima facie evidence that a conclusion was out of date, such as the withdrawal of a drug … Recently published RCTs examined different doses of the drug and demonstrated minimal additional or … The drug needed to be given to eight older patients to achieve more than a 50 percent reduction in … The drug needed to be given to eight older patients to achieve more than a 50 percent reduction in UI

465. Introduction (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-medicine-1_research.pdf
     February 01, 2009 - used to identify adults with both a diagnosis of RA and at least one disease modifying anti-rheumatic drug … Register, other investigators reported that 18% of patients who initially met ACR criteria for RA were in drug-free … Trends in prescription drug expenditures by Medicaid enrollees. … A Blue Report on High Prescription Drug Use in Tennessee and its Consequences. Blue Series.

466. Research Protocol: Diabetes Medications for Adults With Type 2 Diabetes: An Update Focused on Monotherapy and Add-On Therapy to Metformin (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/diabetes-update-2015_research-protocol.pdf
     January 01, 2015 - Food and Drug Administration (FDA) for treatment of type 2 diabetes. … benefit and risk attributable to these drugs or may alter the strength of evidence on some of the drug … Center for Drug Evaluation and Research. Guidance for Industry. … Food and Drug Administration. … FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions

467. Autoimmune Diseases | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/autoimmune-diseases?page=1
     March 09, 2010 - Arthritis Systematic Review Archived November 19, 2007 Comparative Effectiveness of Drug

468. women-hiv-protocol-160301 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/women-hiv_research-protocol.pdf
     March 01, 2016 - lives because of effective ART treatment.15 The effect of hormonal replacement therapy, as well as drug … /drug interactions with antiretroviral treatments, is also not well elucidated. … The problem of drug/drug interactions and possible increased side effects between antiretrovirals and … HIV infection, drug use, and onset of natural menopause. … Management of HIV/AIDS in older patients- drug/drug interactions and adherence to antiretroviral therapy

469. S116 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/s116.pdf
     October 01, 2007 - The PACE drug benefit pays for all outpatient drug treatment with a small copayment from $6 to $10. … APM initiators to guard against selection bias among prevalent users from early symptom emergence, drug … Frequency of Concomitant Prescribing of Tricyclic Antidepressants and Antipsychotic Medications Drug … Therefore, the method is most appropriately used to assess very short-term drug effects in which such … Pharmacoepidemiol Drug Saf. 2006;15:291–303. 19. Sturmer T, Schneeweiss S, Avorn J, et al.

470. Template for Reports Developed (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/allergy-seasonal_research-protocol.pdf
     March 08, 2012 - Food and Drug Administration (FDA) for the treatment of SAR. … Drug class review: nasal corticosteroids: final report update 1. … Drug class review: newer antihistamines: final report update 2. … Food and Drug AdministrationCenter for Drug Evaluation and Research. … Food and Drug Administration; April 2000.

471. Disposition of Comments Report for CER 132 Combination Therapy Versus Intensification of Statin Monotherapy: An Update (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/high-cholestorol-medicines-update_disposition-comments.pdf
     September 01, 2014 - It is now understood that cIMT changes induced by drug therapies do not consistently reflect effects … Public reviewer #2AbbVie Introduction Table 1 shows the relative effect of different drug classes … If high drop-out rates due to the drug, efficacy will by necessity by more limited. … We have added this summary information regarding effect on LDL to the SOE tables for each drug. … pg 195, line 4—“Drug is not” what?

472. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … MG01CI is an extended-release version of metadoxine, a drug originally prescribed for treating acute

473. Urinary-Incontinence-Treatment Research-Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/urinary-incontinence-treatment_research-protocol.pdf
     September 30, 2010 - Drug therapy for stress urinary incontinence:18 Seratonin-noradrenaline uptake inhibitors: Duloxetine … - We will review the effects of different drug formulations (by doses and routes of administration … Eligible interventions of drug therapies or nonsurgical treatments. … The regulatory documents include medical and statistical reviews from the FDA, Health Canada - Drug … Food and Drug Administration, 5630 Fishers Lane, Room 1061.

474. Crosscutting-Horizon-Scan-High-Impact-1506 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1506.pdf
     June 01, 2015 - Food and Drug Administration (FDA) in May 2013. … Once activated, the sensor transmits digital information regarding the drug taken, its dose, and … Food and Drug Administration (FDA). 510(k) summary for Raisin personal monitor [K093976]. … Food and Drug Administration (FDA); 2010 Mar 25 [accessed 2010 Dec 27]. [10 p]. … Food and Drug Administration (FDA); 2012 May 14. 10 p.

475. Does the use of Cytochrome P450 2C19 (CYP2C19) testing to predict response to clopidogrel in people: (1) with acute coronary syndrome, (2) who have suffered other cardiovascular disease-related events (e.g., ischemic stroke, symptomatic… | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/get-involved/nominated-topics/does-the-use-of-cytochrome-p450-2c19-cyp2c19-testing-to-predict-response-to-clopidogrel-in-people-1-with-acute-coronary-syndrome-2-who-have-suffered-other-cardiovascular-disease-related-events-eg-ischemic-stroke-symptomatic-
     November 01, 2017 - Potential for 1) misinterpretation or misclassification of drug metabolizer status, along with the possibility … that it might result in excessive or inadequate dosing, and 2) selection of alternate drug that proves … Appropriateness for EHC Program Does your question include a health care drug, intervention, device

476. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/hepatitis-c-treatment-adherence_research-protocol.pdf
     September 13, 2011 - Food and Drug Administration (FDA) approved protease inhibitors (boceprevir and telaprevir) as a treatment … existing antiviral drugs, and the duration of treatment may change with the introduction of the new drug … programs, medication use training), increasing the convenience of medication use (e.g., simplifying drug … Food and Drug Administration; HCV = hepatitis C virus; KQ = key question; RCT = randomized controlled … We will record authors’ definitions of SVR, drug resistance, histological response, and quality of

477. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/angina-heart-attack-treatments_research-protocol.pdf
     December 11, 2012 - metabolic conversion takes place via the hepatic cytochrome P-450 isoenzymes and is susceptible to drug … Adverse drug reactions (thrombocytopenia, allergic drug reaction) 2. … reactions (thrombocytopenia, allergic drug reaction), bleeding, and stent thrombosis None 14 … The safety outcomes will be framed to help identify adverse events, including adverse drug reactions … ™ Drug-eluting stent Abbott Vascular FDA approved DESyne™ novolimus- eluting stent Drug-eluting stent

478. Data-Points-8 Tables1 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/data-points-8_tables1.pdf
     January 01, 2009 - Total Drug Cost and Out-of-Pocket Cost, by Antihypertensive Drug Class, Among Medicare Parts A, B, and … Total Drug Cost Total Out-of- Pocket Pay- ment Total Drug Cost Total Out-of- Pocket Pay … Total Drug Cost Total Out-of- Pocket Pay- ment Total Drug Cost Total Out-of- Pocket Pay … Total Drug Cost, by Antihypertensive Drug Class, Among Medicare Parts A, B, and D Beneficiaries With … Dartmouth Atlas of Health Care Maps of Total Drug Cost by Antihypertensive Drug Class Among Medicare

479. Use of Antiplatelet Therapy in Patients Receiving Coronary Stents | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/coronary-stents-antiplatelet-therapy/abstract
     November 01, 2017 - Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: … Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting

480. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/diabetic-neuropathy/research-2017
     April 01, 2020 - duloxetine and venlafaxine (moderate SOE), the anticonvulsants pregabalin and oxcarbazepine (low SOE), the drug